Land: Canada
Sprog: engelsk
Kilde: Health Canada
DAPAGLIFLOZIN
AURO PHARMA INC
A10BK01
DAPAGLIFLOZIN
10MG
TABLET
DAPAGLIFLOZIN 10MG
ORAL
15G/50G
Prescription
Active ingredient group (AIG) number: 0156370002; AHFS:
APPROVED
2023-05-16
AURO-DAPAGLIFLOZIN Page 1 of 71 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR AURO-DAPAGLIFLOZIN Dapagliflozin Tablets Tablets, 5 mg and 10 mg, Oral Sodium-glucose co-transporter 2 (SGLT2) inhibitors ATC Code: A10BK01 Auro Pharma Inc. 3700 Steeles Avenue West, Suite # 402 Woodbridge, Ontario, L4L 8K8, Canada. Date of Initial Authorization: September 26, 2022 Submission Control Number: 260267 AURO-DAPAGLIFLOZIN Page 2 of 71 RECENT MAJOR LABEL CHANGES NA TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ...................................................................................................... 2 TABLE OF CONTENTS ........................................................................................................................ 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................ 4 1. INDICATIONS ................................................................................................................................ 4 1.1 Pediatrics ................................................................................................................................ 4 1.2 Geriatrics ................................................................................................................................ 4 2. CONTRAINDICATIONS ................................................................................................................... 5 3. SERIOUS WARNINGS AND PRECAUTIONS BOX .............................................................................. 5 4. DOSAGE AND ADMINISTRATION .................................................................................................. 5 4.1 Dosing Considerations ........................................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ............................................................. Læs hele dokumentet